Although effective anti-neoplastic agents, anthracyclines are limited by their well recognized
and pervasive cardiotoxic effects. The incidence of late progressive cardiovascular disease …

Anthracycline is a mainstay in treatment of many cancers including lymphoma and breast
cancer among many others. However, anthracycline treatment can be cardiotoxic. Although …

The use of anthracyclines is limited by dose-dependent cardiotoxicity. Three forms of
anthracycline cardiotoxicity are described; an immediate pericarditis–myocarditis syndrome …

Cancer diagnostics and therapies have improved steadily over the last few decades,
markedly increasing life expectancy for patients at all ages. However, conventional and …

Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …

Anthracycline chemotherapy causes dose-related cardiomyocyte injury and death leading to
left ventricular dysfunction. Clinical heart failure may ensue in up to 5% of high-risk patients …

Anthracycline antibiotics are widely used antineoplastic agents and their efficacy for the
treatment of various haemopoietic or solid tumours has been well established in clinical …

Purpose: To review the current understanding of the clinical significance, detection,
pathogenesis, and prevention of anthracycline-induced cardiotoxicity. Data Sources: A …

Anthracyclines, such as doxorubicin and idarubicin, remain an important class of
chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a …

Anthracyclines are one of the most commonly used antineoplastic agent classes, and a core
part of the treatment in breast cancers, hematological malignancies, and sarcomas. Their …